PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

British Journal of Haematology

Volumn 129, Issue 6, 2005, Pages 755-762

  Oakervee, Heather E ^a   Popat, Rakesh ^a   Curry, Nicola ^a   Smith, Pat ^a   Morris, Curly ^b   Drake, Mary ^b   Agrawal, Samir ^a   Stec, Jim ^c   Schenkein, David ^c   Esseltine, Dixie Lee ^c   Cavenagh, Jamie D ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Bortezomib; Dexamethasone; Doxorubicin; Multiple myeloma

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CHEMOTHERAPY INDUCED EMESIS; CHEST INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENTIATION; DRUG WITHDRAWAL; FEMALE; HEART ATRIUM FIBRILLATION; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; INFECTION; MALE; MULTIPLE MYELOMA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PYRAZINES; TREATMENT OUTCOME;

EID: 21344435052     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05519.x     Document Type: Article

References (38)

1. Adams, J. (2004) The proteasome: a suitable antineoplastic target. Nature Reviews Cancer, 4, 349-360.
2. Adams, J., Palombella, V.J., Sausville, E.A., Johnson, J., Destree, A., Lazarus, D.D., Maas, J., Pien, C.S., Prakash, S. & Elliott, P.J. (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Research, 59, 2615-2622.
3. Alexanian, R., Weber, D., Giralt, S., Dimopoulos, M., Delasalle, K., Smith, T. & Champlin, R. (2001) Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplantation, 27, 1037-1043.
4. Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. & Bataille, R. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. The New England Journal of Medicine, 335, 91-97.
5. Attal, M., Harousseau, J.L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., Voillat, L., Sotto, J.J., Grosbois, B. & Bataille, R. (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. The New England Journal of Medicine, 349, 2495-2502.
6. Barlogie, B., Shaughnessy, J., Tricot, G., Jacobson, J., Zangari, M., Anaissie, E., Walker, R. & Crowley, J. (2004) Treatment of multiple myeloma. Blood, 103, 20-32.
7. Bataille, R. & Harousseau, J.L. (1997) Multiple myeloma. The New England Journal of Medicine, 336, 1657-1664.
8. Berenson, J., Yang, H., Swift, R., Sadler, K., Vescia, R., Adams, J. & Schenkein, D. (2004) Bortezomib in combination with melphalan in the treatment of relapsed or refractory multiple myeloma: a phase I/II study. Blood, 104, 64a.
9. Bladé, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology, 102, 1115-1123.
10. Cavenagh, J.D. & Oakervee, H. (2003) Thalidomide in multiple myeloma: current status and future prospects. British Journal of Haematology, 120, 18-26.
11. Child, J.A., Morgan, G.J., Davies, F.E., Owen, R.G., Bell, S.E., Hawkins, K., Brown, J., Drayson, M.T. & Selby, P.J. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. The New England Journal of Medicine, 348, 1875-1883.
12. Davies, F.E., Forsyth, P.D., Rawstron, A.C., Owen, R.G., Pratt, G., Evans, P.A., Richards, S.J., Drayson, M., Smith, G.M., Selby, P.J., Child, J.A. & Morgan, G.J. (2001) The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. British Journal of Haematology, 112, 814-819.
13. Hideshima, T., Mitsiades, C., Akiyama, M., Hayashi, T., Chauhan, D., Richardson, P., Schlossman, R., Podar, K., Munshi, N.C., Mitsiades, N. & Anderson, K.C. (2003) Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood, 101, 1530-1534.
14. Hideshima, T., Bergsagel, P.L., Kuehl, W.M. & Anderson, K.C. (2004) Advances in biology of multiple myeloma: clinical applications. Blood, 104, 607-618.
15. Jacobson, J.L., Hussein, M.A., Barlogie, B., Durie, E.G. & Crowley, J.J. (2003) A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. British Journal of Haematology, 122, 441-450.
16. Kuehl, W.M. & Bergsagel, P.L. (2002) Multiple myeloma: evolving genetic events and host interactions. Nature Reviews Cancer, 2, 175-187.
17. Kumar, A., Loughran, T., Alsina, M., Durie, E.G. & Djulbegovic, B. (2003) Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncology, 4, 293-304.
18. Lee, A.H., Iwakoshi, N.N., Anderson, K.C. & Glimcher, L.H. (2003) Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proceedings of the National Academy of Sciences of the United States of America, 100, 9946-9951.
19. Ma, M.H., Yang, H.H., Parker, K., Manyak, S., Friedman, J.M., Altamirano, C., Wu, Z.Q., Borad, M.J., Frantzen, M., Roussos, E., Neeser, J., Mikail, A., Adams, J., Sjak-Shie, N., Vescio, R.A. & Berenson, J.R. (2003) The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clinical Cancer Research, 9, 1136-1144.
20. McElwain, T.J. & Powles, R.L. (1983) High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet, 2, 822-824.
21. Mitsiades, N., Mitsiades, C.S., Poulaki, V., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C, Joseph, M., Libermann, T.A., Treon, S.P., Munshi, N.C., Richardson, P.C., Hideshima, T. & Anderson, K.C. (2002a) Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proceedings of the National Academy of Sciences United States of America, 99, 14374-14379.
22. Mitsiades, N., Mitsiades, C.S., Poulaki, V., Chauhan, D., Richardson, P.G., Hideshima, T., Munshi, N., Treon, S.P. & Anderson, K.C. (2002b) Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood, 99, 4079-4086.
23. Mitsiades, N., Mitsiades, C.S., Richardson, P.G., Poulaki, V., Tai, Y.T., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Schlossman, R., Munshi, N.C., Hideshima, T. & Anderson, K.C. (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood, 101, 2377-2380.
24. National Cancer Institute (2004) National Cancer Institute Therapy Evaluation Program Common Toxicity Criteria, Version 2.0. Available at: http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf, accessed on 24 August 2004.
25. Orlowski, R.Z., Stinchcombe, T.E., Mitchell, B.S., Shea, T.C., Baldwin, A.S., Stahl, S., Adams, J., Esseltine, D.L., Elliott, P.J., Pien, C.S., Guerciolini, R., Anderson, J.K., Depcik-Smith, N.D., Bhagat, R., Lehman, M.J., Novick, S.C., O'Connor, O.A. & Soignet, S.L. (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.. Journal of Clinical Oncology, 20, 4420-4427.
26. Orlowski, R.Z., Voorhees, P.M., Garcia, R.A., Hall, M.D., Adams, J., Esseltine, D.L., Gabriel, D.A., Shea, T.C., van Deventer, H.W., Mitchell, B.S. & Dees, E.G. (2004) Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. The Hematology Journal, 5 (suppl. 2), S131.
27. Patriarca, F., Sperotto, A., Fili, C., Zaja, F., Prosdocimo, S. & Fanin, R. (2002) Early chemosensitivity to VAD regimen predicts a favorable outcome after autologous stem cell transplantation in multiple myeloma. Haematologica, 87, 779-781.
28. Rajkumar, S.V., Hayman, S., Gertz, M.A., Dispenzieri, A., Lacy, M.Q., Greipp, P.R., Geyer, S., Iturria, N., Fonseca, R., Lust, J.A., Kyle, R.A. & Witzig, T.E. (2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of Clinical Oncology, 20, 4319-4323.
29. Rajkumar, S.V., Blood, E., Vesole, D.H., Shepard, R. & Greipp, P.R. (2004) A randomized phase III trial of thalidomide plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma (E1A00): a trial coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 22 (Suppl 14s), 560s.
30. Richardson, P.G., Schlossman, R.L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L.P., Doss, D., Kelly, K., McKenney, M., Mechlowicz, J., Freeman, A., Deocampo, R., Rich, R., Ryoo, J.J., Chauhan, D., Balinski, K., Zeldis, J. & Anderson, K.C. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100, 3063-3067.
31. Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S.A., Lee, S., Hideshima, T., Esseltine, D.L., Kauffman, M., Adams, J., Schenkein, D.P. & Anderson, K.C. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. The New England Journal of Medicine, 348, 2609-2617.
32. Richardson, P., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Dalton, W.S., Harrousseau, J.-L., San Miguel, J.F. & Anderson, K.C. (2004) Bortezomib vs. dexamethasone in relapsed multiple myeloma: a phase 3 randomized study. Journal of Clinical Oncology, 22 (Suppl 14s), 560s.
33. Segeren, C.M., Sonneveld, P., van der Holt, B., Baars, J.W., Biesma, D.H., Cornellissen, J.J., Croockewit, A.J., Dekker, A.W., Fibbe, W.E., Lowenberg, B., van Marwijk, K.M., van Oers, M.H., Richel, D.J., Schouten, H.C., Vellenga, E., Verhoef, G.E., Wijermans, P.W., Wittebol, S. & Lokhorst, H.M. (1999) Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. British Journal of Haematology, 105, 127-130.
34. Segeren, C.M., Sonneveld, P., van der Holt, B., Vellenga, E., Croockewit, A.J., Verhoef, G.E., Cornelissen, J.J., Schaafsma, M.R., van Oers, M.H., Wijermans, P.W., Fibbe, W.E., Wittebol, S., Schouten, H.C., van Marwijk, K.M., Biesma, D.H., Baars, J.W., Slater, R., Steijaert, M.M., Buijt, I. & Lokhorst, H.M. (2003) Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood, 101, 2144-2151.
35. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J. & Barlogie, B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. The New England Journal of Medicine, 341, 1565-1571.
36. The UK Myeloma Forum Guidelines Working Group (2001) Diagnosis and management of multiple myeloma. British Journal of Haematology, 115, 522-540.
37. Weber, D., Rankin, K., Gavino, M., Delasalle, K. & Alexanian, R. (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. Journal of Clinical Oncology, 21, 16-19.
38. Zangari, M., Barlogie, B., Jacobson, J., Rasmussen, E., Burns, M., Kordsmeier, B., Shaughnessy, I.D., Anaissie, E.J., Thertulien, R., Fassas, A., Lee, C.K., Schenkein, D., Zeldis, J.B. & Tricot, G. (2003) VTD regimen comprising Velcade (V) + thalidomide (T) and added DEX (D) for non-responders to V + T effects a 57% PR rate among 56 patients with myeloma (M) relapsing after autologous transplant. Blood, 102, 236a.